Tralokinumab对未控制中重度哮喘气道嗜酸性炎症的影响(MESOS):2期随机对照试验
MESOS是一项多中心、双盲、随机、安慰剂对照2期试验,纳入79例未控制中重度哮喘患者,评估IL-13中和单抗tralokinumab对气道嗜酸性炎症的影响。提示IL-13并非中重度哮喘嗜酸性气道炎症控制的关键因素。
要点
- tralokinumab未显著减少支气管黏膜、血或痰嗜酸性粒细胞。
- tralokinumab显著降低FeNO和血总IgE浓度。
- 提示IL-13不是中重度哮喘嗜酸性气道炎症的关键调控因子。
核心结论
- 与安慰剂相比,tralokinumab未显著影响支气管黏膜下、血或痰中的嗜酸性炎症,但降低了FeNO和IgE浓度。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照2期试验,在英国、丹麦和加拿大15个中心开展。
- 纳入18-75岁、未控制中重度哮喘≥12个月且需稳定剂量吸入糖皮质激素治疗的患者。
- 79例受试者按1:1随机接受tralokinumab 300 mg(n=39)或安慰剂(n=40),每2周皮下注射。
- 主要终点为第12周支气管活检嗜酸性粒细胞计数较基线的变化。
临床怎么用
- 中重度哮喘患者不应基于嗜酸性气道炎症选择IL-13中和单抗tralokinumab。
- tralokinumab可降低FeNO和IgE,但需进一步研究其临床获益人群。
局限性
- 样本量较小(79例随机分组)。
- 研究为2期试验,主要终点为替代标志物而非临床结局。
- 未报告按生物标志物分层的亚组分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of interleukin 13 in airway inflammation and remodelling in asthma is unclear. Tralokinumab is a human monoclonal antibody that neutralises interleukin 13. We aimed to evaluate whether tralokinumab would have an effect on airway eosinophilic infiltration, blood and sputum eosinophil concentrations, eosinophil activation, and airway remodelling. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled phase 2 trial at 15 centres across the UK, Denmark, and Canada. We enrolled participants of either sex aged 18-75 years with inadequately controlled moderate-to-severe asthma for 12 months or more, requiring treatment with inhaled corticosteroids at a stable dose. We randomly assigned participants (1:1) to receive tralokinumab (300 mg) or placebo by an interactive web-based system or voice response system. Participants and study personnel were masked to treatment allocation. Both tralokinumab and placebo were administered subcutaneously every 2 weeks. The primary outcome measure was change from baseline to week 12 in bronchial biopsy eosinophil count. Secondary outcome measures included change in blood and sputum eosinophil counts. Exploratory outcomes included fractional exhaled nitric oxide (FENO) and blood IgE concentrations. Safety analyses were carried out in all participants who received study drug. This trial is registered with ClinicalTrials.gov, number NCT02449473, and with the European Clinical Trials Database, EudraCT 2015-000857-19. FINDINGS: Between Sept 25, 2015, and June 21, 2017, 224 participants were enrolled and screened. Of these participants, 79 were randomly assigned to receive tralokinumab (n=39) or placebo (n=40). Tralokinumab did not significantly affect bronchial eosinophil count compared with placebo at week 12 (treatment effect ratio 1·43, 95% CI 0·63-3·27; p=0·39). Compared with placebo, tralokinumab did not significantly affect blood eosinophil count (treatment effect ratio 1·21, 95% CI 1·00-1·48; p=0·055) or sputum eosinophil count (0·57, 0·06-6·00; p=0·63), but FENO concentration (0·78, 0·63-0·96; p=0·023) and total blood IgE concentration (0·86, 0·77-0·97; p=0·014) were significantly reduced. 33 (85%) of 39 patients receiving tralokinumab and 32 (80%) of 40 receiving placebo reported at least one adverse event during the treatment period. No deaths in either treatment group were observed. Treatment-related adverse events occurred more frequently in the tralokinumab group than in the placebo group (11 [28%] of 39 vs seven [18%] of 40). INTERPRETATION: Tralokinumab did not significantly affect eosinophilic inflammation in bronchial submucosa, blood, or sputum compared with placebo, but did reduce FENO and IgE concentrations. These results suggest interleukin 13 is not crucial for eosinophilic airway inflammation control in moderate-to-severe asthma. FUNDING: AstraZeneca.
引用
- Russell RJ, Chachi L, FitzGerald JM, et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respir Med. 2018. PMID: 29793857. doi:10.1016/S2213-2600(18)30201-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。